About: Marie Wislez

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Marie Wislez Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Wislez, Marie Wislez, Marie Wislez, Marie Wislez, Marie
bnf-onto:FRBNF	16944017(xsd:integer)
preferred label	Wislez, Marie
name	Marie Wislez
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
isni:identifierValid	0000000139470155
Given name	Marie
familyName	Wislez
has biographical i...tion (Deprecated)	Directeur de thèse d'exercice de médecine à l'Université Paris Diderot - Paris 7 Auteur d'une thèse de doctorat en Physiologie et physiopathologie de la circulation et de la respiration. Respiration soutenue en 2003 à l'Université de Paris 6
gender	female
ORCID iD	0000-0001-7518-7859
Scopus ID	6701766796
is sameAs of	Wislez, Marie Wislez, Marie Wislez, Marie
is Thesis advisor of	http://www.sudoc.fr/190675446/id http://www.sudoc.fr/185473822/id http://www.sudoc.fr/200869086/id http://www.sudoc.fr/16971117X/id http://www.sudoc.fr/181823608/id http://www.sudoc.fr/160460077/id http://www.sudoc.fr/190154667/id http://www.sudoc.fr/260691399/id Expression de PD-L1 et DLL3 et rôle pronostique dans le cancer bronchique à petites cellules http://www.sudoc.fr/260691550/id http://www.sudoc.fr/277728592/id
is Praeses of	http://www.sudoc.fr/185086470/id http://www.sudoc.fr/191819816/id
is Author of	http://www.sudoc.fr/089425731/id Sarcoidosis in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors https://hal.archives-ouvertes.fr/hal-02104986#id Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial https://hal.archives-ouvertes.fr/hal-02570654#id Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. Efficacité des inhibiteurs de checkpoint immunitaire dans le carcinome sarcomatoïde du poumon : données issues d'une cohorte française multicentrique Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank Improvement of Symptomatic Human Immunodeficiency Virus-Related Lymphoid Interstitial Pneumonia in Patients Receiving Highly Active Antiretroviral Therapy Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes Short-term and Long-term Outcomes of Patients With Lung Cancer and Life-Threatening Complications Les réarrangements moléculaires : cibles thérapeutiques en cancérologie thoracique High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Immunodynamics of explanted human tumors for immuno-oncology http://www.sudoc.fr/24682770X/id Rôle des polynucléaires neutrophiles dans la progression aérogène des adénocarcinomes pulmonaires Quels résultats de l’année 2016 vont avoir un impact sur nos pratiques ? Le point de vue du Comité de rédaction du Bulletin du Cancer Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers https://archive-ouverte.unige.ch/unige:47106#id EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors Les points chauds de l’actualité en 2017. Une sélection du comité de rédaction du Bulletin du Cancer Nivolumab-refractory patients with advanced non-small-cell lung cancer http://www.sudoc.fr/053686896/id Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Étude BRIGALK. https://serval.unil.ch/notice/serval:BIB_9F4BC4C6EF7B#id La réintroduction de chimiothérapie est-elle faisable au cours du traitement du cancer pulmonaire non à petites cellules de stade avancé ? Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy Regulator of telomere length 1 ( RTEL1 ) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes Long-Term Imaging Follow-Up in DIPNECH: Multicenter Experience Les tumeurs thoraciques SMARCA4 déficientes : une nouvelle entité Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy 2015 through the eyes of the Bulletin of Cancer editorial board VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study) Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice [IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer]. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Les mutations des sites d’épissage de l’exon 14 de MET. Une nouvelle opportunité thérapeutique dans le cancer du poumon https://serval.unil.ch/notice/serval:BIB_A9F032E17471#id Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicenter real-life cohort study https://serval.unil.ch/notice/serval:BIB_72EF703BC03A#id https://serval.unil.ch/notice/serval:BIB_663787DE1313#id Sleep Traits, Night Shift Work and Lung Cancer Risk among Women: Results from a Population-Based Case-Control Study in France (The WELCA Study) Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
is primary topic of	http://www.idref.fr/089425774
is Publishing director of	http://www.sudoc.fr/183809904/id
is Opponent of	http://www.sudoc.fr/224007149/id http://www.sudoc.fr/223470368/id http://www.sudoc.fr/277256569/id
is Thesis referee of	http://www.sudoc.fr/169904628/id

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software